RYAN COMMISKEY: Open Payments
NPI 1922510577 · SANTA FE, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,596 in 199 payments from 50 companies in 2025. Trend: 2023 $4,096 · 2024 $4,806 · 2025 $4,596
Food & beverage: $3,798Long term medical supply or device loan: $798
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 31 | $1,234 |
| Janssen Biotech, Inc. | 13 | $256 |
| ABBVIE INC. | 7 | $204 |
| AstraZeneca Pharmaceuticals LP | 12 | $201 |
| Daiichi Sankyo Inc. | 8 | $201 |
| Celgene Corporation | 17 | $193 |
| Merck Sharp & Dohme LLC | 9 | $174 |
| E.R. Squibb & Sons, L.L.C. | 10 | $159 |
| GENZYME CORPORATION | 5 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $109 |
Products named: KISQALI, ENHERTU, KEYTRUDA, REBLOZYL, PLUVICTO, SARCLISA, VENCLEXTA, Orserdu.
Industry payments across NM — which companies pay providers there.
